Definitive Healthcare (DH) Stifel 2024 Cross Sector Insight Conference summary

Business overview and product strategy

• Provides deep, proprietary healthcare data and analytics to help clients commercialize in the healthcare ecosystem, serving biotech, medtech, providers, and diversified companies.

• Data is collected via first-party outreach, public sources, government agencies, and third-party claims data, covering 300 million patients.

• AI and data science are used to link, extrapolate, and generate new insights, including identifying key market influencers.

• Focus on self-service analytics tools, enabling clients to access and iterate on data in real time, reducing time to value.

• Recent acquisition of Populi enhances analytics and visualization capabilities, now being expanded across all client segments.

Go-to-market and operational changes

• Major restructuring in January focused on cost reduction and realignment for a slower growth environment.

• Shifted resources to large enterprise clients ($100K+ contracts) for deeper penetration and higher renewal rates.

• SMID clients moved to a high-volume, transactional sales approach for efficiency.

• Early-year pipeline growth was slow due to restructuring but has since rebounded to historical levels.

Market dynamics and competitive landscape

• Does not directly compete with Crossix; focuses less on digital marketing analytics.

• Provider and diversified client segments are recovering, while biotech and big pharma remain cautious due to macro and regulatory factors.

• Biotech financing is seen as a leading indicator for broader industry recovery.